Dicus Melissa, Lyons Barry, Olson Colleen, Tran David A, Blackburn David F
College of Pharmacy and Nutrition, University of Saskatchewan, Canada.
Saskatoon Cancer Centre, Canada.
J Oncol Pharm Pract. 2015 Dec;21(6):403-8. doi: 10.1177/1078155214537926. Epub 2014 Jun 5.
Chronic use of imatinib confers an important survival benefit for individuals with chronic myeloid leukemia. In Saskatchewan, the provincial cancer agency addresses important barriers to adherence by providing imatinib at no cost through specialized cancer centers.
To describe adherence to imatinib dispensed through the Saskatchewan Cancer Agency.
We conducted a retrospective analysis of electronic pharmacy dispensation records from the Saskatchewan Cancer Agency. All dispensations for imatinib classified for hematologic malignancies were electronically abstracted by cancer center personnel and securely forwarded to investigators with all meaningful patient identifiers removed. All subjects receiving a new dispensation (i.e. using a 6-month washout period) for imatinib between 1 June 2004 and 31 December 2011 were included. The primary endpoint was optimal adherence to imatinib during the first year of therapy, defined as a medication possession ratio ≥ 80%.
Ninety-one subjects were started on imatinib during the observation period. During the first year of therapy, 82.4% (75/91) maintained a medication possession ratio ≥ 80%. The percentage of individuals maintaining optimal adherence decreased only slightly when the observation period was extended to 2 (78.4%) or 3 years (78.8%).
Non-adherence to imatinib is relatively infrequent when provided by the Saskatchewan Cancer Agency.
长期使用伊马替尼可为慢性粒细胞白血病患者带来重要的生存获益。在萨斯喀彻温省，省级癌症机构通过专门的癌症中心免费提供伊马替尼，以消除依从性方面的重要障碍。
描述通过萨斯喀彻温癌症机构发放的伊马替尼的依从性情况。
我们对萨斯喀彻温癌症机构的电子药房配药记录进行了回顾性分析。癌症中心工作人员以电子方式提取了所有归类为血液系统恶性肿瘤的伊马替尼配药信息，并在去除所有有意义的患者标识符后，将其安全地转发给研究人员。纳入了2004年6月1日至2011年12月31日期间所有接受伊马替尼新配药（即采用6个月洗脱期）的受试者。主要终点是治疗第一年对伊马替尼的最佳依从性，定义为药物持有率≥80%。
在观察期内，91名受试者开始使用伊马替尼。在治疗的第一年，82.4%（75/91）的受试者保持药物持有率≥80%。当观察期延长至2年（78.4%）或3年（78.8%）时，保持最佳依从性的个体百分比仅略有下降。
由萨斯喀彻温癌症机构提供伊马替尼时，不依从的情况相对较少。
